Merger includes C$20 million investment to accelerate access to genomics-based testing for cancer treatment by combining Canexia Health’s advanced molecular cancer solutions with Imagia Cybernetics’ healthcare and AI expertise
Read More
enGene Inc., a clinical-stage biotechnology company pioneering novel non-viral gene therapies for local administration into mucosal tissues enabled by its proprietary DDX platform, today announced positive results from its LEGEND study, a first-in-human Phase 1/2 clinical trial of EG-70 for the treatment of high-grade Non-Muscle Invasive Bladder Cancer (NMIBC) in patients with carcinoma in situ (CIS) that are BCG-unresponsive.
Read More
Company founded in 2021 and led by Clarissa Desjardins, Ph.D., previously the founder and chief executive officer of Clementia Pharmaceuticals (now Ipsen). Kenneth J. Valenzano, Ph.D., joins as Chief Scientific Officer, adding to a team with domain experience in rare disease clinical development, computational and medicinal chemistry, and business development
Read More
Adding Verzenio to endocrine therapy demonstrated a significant and clinically meaningful reduction in the risk of recurrence in patients with hormone receptor positive (HR+) and human epidermal growth factor 2 negative (HER2-), node-positive, high risk early breast cancer and a Ki-67 score of ≥20%. Verzenio was first authorized in Canada in 2019 for the treatment of estrogen and/or progesterone HR+ HER2-, metastatic breast cancer (mBC)
Read More
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it has launched an offering of $1.0 billion aggregate principal amount of new senior secured notes due 2027 (the "Notes"). As previously announced, the Company is also seeking to refinance its existing credit agreement (the "Credit Agreement" and such refinancing, the "Credit Agreement Refinancing"). The refinanced Credit Agreement is expected to consist of approximately $2.5 billion of term B loans (the "New Term B Loans") and a $975 million revolving credit facility. The Credit Agreement Refinancing is expected to occur upon completion of the initial public offering ("IPO") of Bausch + Lomb Corporation ("Bausch + Lomb" and such offering, the "Bausch + Lomb IPO") and a related debt financing by Bausch + Lomb (the "Bausch + Lomb Debt Financing").
Read More
Inversago Pharma Inc. (“Inversago”), the peripheral CB1 blockade company, announced today the successful completion of the Phase 1 Clinical Trial for its INV-202 molecule that focuses on treating metabolic disorder complications. Favorable safety, tolerability and pharmacokinetic results from the trial warrant further investigation, and the Company will actively pursue the advancement of INV-202 into later-stage clinical trials.
Read More
Carebook Technologies Inc. ("Carebook" or the "Company") (TSXV: CRBK) (OTCPK: CRBKF) (XETR: PMM1), a leading Canadian provider of innovative digital health solutions, announced today that they will be working with LifeLabs, Canada's largest community medical laboratory network, to deliver valuable insights to LifeLabs' MyCareCompass customers through integration with Carebook's CoreHealth Assessment Tool. This multi-year licensing agreement will deliver even greater value to LifeLabs' customers, empowering them to conveniently manage their healthcare through MyCareCompass.
Read More
CQDM is pleased to announce a grant for a collaboration between McGill University, Neurasic Therapeutics, McGill University’s Healthy Brains, Healthy Lives (HBHL) initiative and the Louise and Alan Edwards Foundation.
Read More
Immune Biosolutions Inc., a clinical-stage company, is pleased to announce that its leading biological drug candidate maintains a potent activity in neutralization assays. Recent results have confirmed that this drug, IBIO123, is capable of neutralizing SARS-CoV-2 (COVID-19) and all its current variants of concern (VOCs) that have emerged throughout the pandemic, including the latest Omicron variant. IBIO123 is an inhaled antibody-based immunotherapy with an ongoing multisite phase 1 and 2 clinical program for the treatment of symptomatic SARS-CoV-2 patients.
Read More
Clinical benefit (complete responses, partial responses, and stable disease) observed in metastatic bladder cancer patients, including those who had received prior immune checkpoint inhibitor therapy
Read More
Valence Discovery, a leader in AI-first design of novel chemistry against previously intractable biology, announced today that it has closed an oversubscribed US$7 million seed financing. The financing, which was co-led by Fifty Years and Air Street Capital, with participation from Amplitude Ventures, Phoenix Venture Partners, and Abcam founder and former CEO, Jonathan Milner, adds to US$1.5 million raised previously, bringing Valence’s total seed funding to US$8.5 million. The new funds will support expanding Valence’s AI-based generative chemistry engine, scaling its partnerships with world-class discovery organizations, further building a leading team of interdisciplinary scientists, and advancing internal drug discovery efforts.
Read More
MONTREAL--(BUSINESS WIRE)--Laurent Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (“FDA”) has allowed the Phase 2 RESOLUTION study extension in hospitalized moderate-to-severe adult COVID-19 patients and the change of the primary endpoint to “proportion of patients requiring mechanical ventilation and/or death by Day 60.” The company also announced that the FDA has granted a Type B meeting request to discuss, among other topics, the eligibility to Emergency Use Authorization (EUA) and Phase 3 clinical trials with LAU-7b in COVID-19, in both hospitalized and ambulatory settings. The meeting will take place on January 14th, 2022, via conference call.
Read More
LAVAL, Quebec--(BUSINESS WIRE)--Dec. 13, 2021-- BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related disorders, today announced that the 50 mg and 200 mg BID doses of BLU-5937 in its Phase 2b SOOTHE trial for the treatment of RCC achieved statistical significance on the primary endpoint with 34% placebo-adjusted reduction in 24-hour cough frequency observed (p ≤ 0.005) at day 28. BLU-5937 was generally well-tolerated, with low rates of taste-related adverse events reported (≤6.5%) at all doses.
Read More
During this Lung Cancer Awareness Month, CQDM is proud to announce that it will co-fund a project driven by Dr Philippe Joubert and Pr. Yohan Bossé at the Quebec Heart and Lung Institute (Institut Universitaire de Cardiologie et Pneumologie du Québec-Université Laval – IUCPQ-UL) targeting a program of early-stage detection of lung cancer. Funding for this collaborative research project is made possible with the financial support of the ministère de l’Économie et de l’Innovation (MEI) who will be providing $1.36M as part of CQDM’s SynergiQC program.
Read More
For the first time, maveropepimut-S is being evaluated in a neoadjuvant combination and in patients with breast cancer
Read More
Vimian Group has signed an agreement to develop new vaccines for allergy and atopic dermatitis together with Angany, a Canadian biotechnology company focused on the development of novel bioparticle-based vaccines.
Read More
NeuroScientific Biopharmaceuticals will utilise Imeka's cutting edge diffusion MRI tech to help identify disease modifying effect in the brain.
Read More
adMare BioInnovations and the Canadian Alliance for Skills and Training in Life Sciences (CASTL) are pleased to announce their new partnership to train industry-ready talent for Canada’s biopharmaceutical manufacturing sector.
Read More
Angany Inc., announces today that it has entered into a partnering agreement with Dr. Wayne Shreffler, MD, PhD, Chief, Division of Pediatric Allergy & Immunology and Director of the Food Allergy Center at Massachusetts General Hospital and MassGeneral Hospital for Children, for a comprehensive series of preclinical studies of Angany’s peanut allergy biologic candidate BP/AH-01.
Read More